SCHEMBL4682191

SCHEMBL4682191

CCOC(=O)c1ccc2c(c1)CCCN2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.62
KDM4E B2RXH2 3/20 0.62
ALDH1A1 P00352 3/20 0.54
ALOX15 P16050 3/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
GAA P10253 3/20 0.48
HSD17B10 Q99714 2/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
THRB P10828 1/20 0.48
CASP1 P29466 1/20 0.48
HTT P42858 1/20 0.48
CASP7 P55210 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA12 O43570 3/20 0.48
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA9 Q16790 3/20 0.48
CA7 P43166 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30853462 1.00 MAPT (0.62) MAPTKDM4EALDH1A1ALOX15CYP2C9
SCHEMBL29995197 0.84 MAPT (0.68) MAPTKDM4EALDH1A1ALOX15CYP2C9
SCHEMBL45146 0.84 MAPT (0.68) MAPTKDM4EALDH1A1ALOX15CYP2C9
Hydrochloric Acid SCHEMBL1856980 0.83 MAPT (0.66) MAPTKDM4EALDH1A1ALOX15CYP2C9
SCHEMBL16585812 0.82 MAPT (0.60) MAPTKDM4EALDH1A1GAALMNA
SCHEMBL30955004 0.82 MAPT (0.60) MAPTKDM4EALDH1A1GAALMNA
SCHEMBL7420967 0.80 MAPT (0.52) MAPTKDM4EALDH1A1ALOX15CYP2C9
SCHEMBL29968115 0.80 JAK2 (0.51) MAPTKDM4EALDH1A1ALOX15CYP2C9
SCHEMBL3872066 0.80 JAK2 (0.51) MAPTKDM4EALDH1A1ALOX15CYP2C9
SCHEMBL30718459 0.80 MAPT (0.54) MAPTKDM4EALDH1A1ALOX15GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486251-B2 CBP/EP300 inhibitor and use thereof PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2025-12-02 US disclosed
CN-115397822-B CBP/EP300 inhibitors and uses thereof 南京药石科技股份有限公司 2024-04-16 CN disclosed
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2023-05-25 US disclosed
EP-4140996-A1 CBP/EP300 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING), INC. (CN) 2023-03-01 EP disclosed
CN-115397822-A CBP/EP300 inhibitors and uses thereof 南京药石科技股份有限公司 2022-11-25 CN disclosed
CN-105189461-B The dibasic 1- acyl groups -4- amino -1,2,3,4- tetrahydroquinoline derivatives of 2,3- and their purposes as bromine domain inhibitor 葛兰素史克知识产权第二有限公司 2018-05-15 CN disclosed
EP-1236712-B1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE AJINOMOTO KK (JP) 2008-08-06 EP disclosed
US-6710056-B2 PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. AJINOMOTO CO., INC. (JP) 2004-03-23 US disclosed
US-20030232868-A1 Cyclic carboxylic acids as integrin antagonists BAYER AKTIENGESELLSCHAFT (DE) 2003-12-18 US disclosed
US-20030109547-A1 Amidinophenylpyruvic acid derivatives AJINOMOTO CO. INC (JP) 2003-06-12 US disclosed
EP-1276714-A2 CYCLIC CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS Bayer Aktiengesellschaft (DE) 2003-01-22 EP disclosed
EP-1236712-A1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-09-04 EP disclosed
WO-2001081298-A2 CYCLIC CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109547-A1 Amidinophenylpyruvic acid derivatives HABP2, F2, F7 MAPT 4059/4885KDM4E 2614/4885ALDH1A1 622/4885
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF EP300, CREBBP, BPTF MAPT 2797/4885KDM4E 440/4885ALDH1A1 2314/4885
US-20030232868-A1 Cyclic carboxylic acids as integrin antagonists ITGA1, ITGB1, ITGA2B MAPT 4196/4885KDM4E 3757/4885ALDH1A1 316/4885
US-12486251-B2 CBP/EP300 inhibitor and use thereof EP300, CREBBP, BPTF MAPT 2797/4885KDM4E 440/4885ALDH1A1 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.